VPRIV requires close monitoring for hypersensitivity reactions, including anaphylaxis, which may occur during or after treatment.

Precautions for VPRIV Use

Patients receiving VPRIV must be closely monitored for hypersensitivity reactions, including life-threatening anaphylaxis, both during the initial and ongoing stages of treatment. It is recommended that VPRIV be initiated in a healthcare setting where immediate medical support, including access to cardiopulmonary resuscitation equipment, is available. If anaphylaxis or other severe hypersensitivity reactions occur, VPRIV should be discontinued, and immediate medical intervention, including the use of epinephrine, should be initiated. Patients should be informed about the symptoms of hypersensitivity reactions and instructed to seek medical attention if symptoms occur.